RO8994 is a potent and selective inhibitor of the enzyme PI3Kδ (phosphoinositide 3-kinase delta), which plays a key role in immune cell signaling. It is primarily investigated for its therapeutic potential in autoimmune and inflammatory diseases. Due to its ability to modulate immune cell activity, RO8994 has shown promise in preclinical models of rheumatoid arthritis, lupus, and other conditions involving dysregulated immune responses. Its selectivity for the delta isoform helps minimize off-target effects, making it a favorable candidate for development in chronic inflammatory conditions. Additionally, RO8994 is used as a research tool to study PI3K signaling pathways in immune cells, aiding in the understanding of disease mechanisms and drug responses.